Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | CTSD | P07339 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11087644 | 0.85 | NPC1 (0.63) | HPGDL3MBTL1KCNA5NPC1KMT2A | |
| SCHEMBL10330502 | 0.84 | KCNA3 (0.70) | HPGDTP53GLACTSDL3MBTL1 | |
| SCHEMBL3038950 | 0.83 | KMT2A (0.74) | HPGDTP53GLACTSDUSP2 | |
| SCHEMBL6360123 | 0.83 | HPGD (0.65) | HPGDTP53GLACTSDUSP2 | |
| SCHEMBL11761482 | 0.83 | NAMPT (0.71) | HPGDTP53GLACTSDL3MBTL1 | |
| SCHEMBL7956519 | 0.81 | HPGD (0.63) | HPGDTP53GLACTSDUSP2 | |
| SCHEMBL3365176 | 0.81 | CTSD (0.68) | HPGDTP53GLACTSDUSP2 | |
| SCHEMBL10243095 | 0.81 | STAT3 (0.64) | HPGDTP53GLACTSDUSP2 | |
| SCHEMBL30848493 | 0.81 | HPGD (0.63) | HPGDTP53GLACTSDUSP2 | |
| Hydrochloric Acid SCHEMBL9585041 | 0.80 | CTSD (0.66) | HPGDTP53GLACTSDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | HPGD 3821/4885TP53 4042/4885GLA 708/4885 |
| US-11840543-B2 | Compounds and uses | NLRP3, NOD1, IAPP | HPGD 1231/4885TP53 1567/4885GLA 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.